News | TCTAP 2022

No ‘one-size-fits-all’ approach to treat CAD with PCI before or after TAVR, heart expert says

Nicolas M. Van Mieghem, MD says more data on impact, timing of coronary intervention on TAVR candidates needed for optimal CAD management

News | TCTAP 2022

Was 2021 a bad year for FFR-guided PCI?

William F. Fearon, MD says analysis of FUTURE, FLOWER-MI and FAME 3 trials show FFR-guided PCI still beneficial for select patients with multivessel CAD

News | TCTAP 2022

‘CABG helps people live longer’

Cardiac surgeon S. Christopher Malaisrie, MD says CABG improves survival for MVD and LMCAD, despite recent guideline downgrades

News | TCTAP 2022

Is CABG the best approach for multivessel, left main CAD?

Mario F.L. Gaudino, MD says PCI and CABG are complementary - not antagonistic – strategies for patients with MVD, LMCAD

News | TCTAP 2022

‘Modern trials on SIHD revascularization show no mortality benefit with CABG over medical therapy’

Sripal Bangalore, MD explains 2021 American revasc guidelines sift out old mortality data, throw weight behind contemporary ones

News | TCTAP 2022

Tailored de-escalation strategy in PCI and ACS: platelet function test and genetic test guidance

At TCTAP 2022, Dominick J. Angiolillo, MD outlines de-escalation strategies with PFT, genetic tests for PCI-ACS

News | TCTAP 2022

Can PCI save lives in severe LV dysfunction?

Divaka Perera, MD says REVIVED-BCIS2 to shed light on revascularization decisions for acute and chronic LV dysfunction